[Prospektives Audit des Gentamicin Drug Monitorings in einem Kinderkrebszentrum].

Autor: Herberger S; Pediatric Oncology and Hematology, Saarland University Hospital and Saarland University Faculty of Medicine, Homburg, Germany., Oberkircher N; Pediatric Oncology and Hematology, Saarland University Hospital and Saarland University Faculty of Medicine, Homburg, Germany., Wenzel GI; Otorhinolaryngology, Saarland University Hospital and Saarland University Faculty of Medicine, Homburg, Germany., Hecker D; Otorhinolaryngology, Saarland University Hospital and Saarland University Faculty of Medicine, Homburg, Germany., Wagenpfeil G; Institute for Medical Biometry, Epidemiology and Medical Informatics, Saarland University Hospital and Saarland University Faculty of Medicine, Homburg, Germany., Furtwängler R; Pediatric Oncology and Hematology, Saarland University Hospital and Saarland University Faculty of Medicine, Homburg, Germany., Becker SL; Center for Infectious Diseases, Institute of Medical Microbiology and Hygiene, Saarland University, Homburg, Germany., Papan C; Center for Infectious Diseases, Institute of Medical Microbiology and Hygiene, Saarland University, Homburg, Germany., Graf N; Pediatric Oncology and Hematology, Saarland University Hospital and Saarland University Faculty of Medicine, Homburg, Germany., Simon A; Pediatric Oncology and Hematology, Saarland University Hospital and Saarland University Faculty of Medicine, Homburg, Germany.
Jazyk: němčina
Zdroj: Klinische Padiatrie [Klin Padiatr] 2021 May; Vol. 233 (3), pp. 123-126. Date of Electronic Publication: 2021 Feb 18.
DOI: 10.1055/a-1352-5053
Abstrakt: Background: Many pediatric cancer centers still use Gentamicin as first line combination treatment in patients with fever and neutropenia. Since 2011, our center has implemented a dosing regimen with 250 mg/m 2 BSA (max. 10 mg/kg, max. 400 mg) as a single daily infusion according to the German guideline.
Patients and Methods: In this prospective audit (February 2011 to December 2019), 105 Gentamicin treatment cycles were analyzed in 66 pediatric cancer patients, focusing on adherence to the dosing regimen and the drug monitoring results.
Results: Adherence to the dosing regimen was high (89%). In 64% of all cycles, the C max (drawn 1 h after the 2 nd dose) reached the target of 10-20 µg/ml. C max significantly correlated with dosing in mg/m 2 BSA (p=0,007), but not with dosing in mg/kg (p=0,366). Age below 6 years did not influence these results. The Gentamicin C trough (drawn 8-10 h after the second dose) was < 2 µg/ml in 93% of all cycles without any dose correlation. None of the patients experienced Gentamicin-associated nephrotoxicity.
Discussion and Conclusion: This prospective audit of single daily infusion Gentamicin in pediatric cancer patients without impaired renal function elicits the feasibility and safety of the dosing regimen in mg/m 2 BSA according to the German guideline. Since indications for first-line gentamicin are limited, a multicenter prospective study would be advantageous to confirm these observations.
Competing Interests: The authors declare that they have no conflict of interest.
(Thieme. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: